Edesa Biotech logo

Edesa BiotechNASDAQ: EDSA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

21 June 2010

Next earnings report:

16 December 2024

Last dividends:

N/A

Next dividends:

N/A
$8.80 M
-92%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 23:59:29 GMT
$2.71-$1.13(-29.43%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

EDSA Latest News

Edesa Biotech's Founder Makes Strategic Investment in the Company
globenewswire.com31 October 2024 Sentiment: POSITIVE

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD, Edesa's Chief Executive Officer and Founder, to invest up to $5.0 million in the company, including an immediate investment of approximately $1.5 million.

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
globenewswire.com13 September 2024 Sentiment: POSITIVE

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
globenewswire.com09 August 2024 Sentiment: POSITIVE

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business.

Edesa Biotech to Participate in Barclays Global Healthcare Conference
Accesswire07 March 2024 Sentiment: NEUTRAL

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings through conference organizers or by contacting the company at [email protected].

What type of business is Edesa Biotech?

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

What sector is Edesa Biotech in?

Edesa Biotech is in the Healthcare sector

What industry is Edesa Biotech in?

Edesa Biotech is in the Biotechnology industry

What country is Edesa Biotech from?

Edesa Biotech is headquartered in Canada

When did Edesa Biotech go public?

Edesa Biotech initial public offering (IPO) was on 21 June 2010

What is Edesa Biotech website?

https://www.edesabiotech.com

Is Edesa Biotech in the S&P 500?

No, Edesa Biotech is not included in the S&P 500 index

Is Edesa Biotech in the NASDAQ 100?

No, Edesa Biotech is not included in the NASDAQ 100 index

Is Edesa Biotech in the Dow Jones?

No, Edesa Biotech is not included in the Dow Jones index

When was Edesa Biotech the previous earnings report?

No data

When does Edesa Biotech earnings report?

The next expected earnings date for Edesa Biotech is 16 December 2024